论文部分内容阅读
目的通过测定脂类代谢有关指标，为早期发现肾脏疾病患者继发性高脂、动脉粥样硬化性心血管并发症提供诊断依据。方法采用免疫透射比浊法及酶法，测定５５例尚无心血管并发症的肾脏病患者及５２例健康人的血清载脂蛋白（Ａｐｏ）Ａ１、Ｂ，高密度脂蛋白胆固醇（ＨＤＬＣ），低密度脂蛋白胆固醇（ＬＤＬＣ）。结果肾病组的ＡｐｏＡ１，ＡｐｏＢ，ＡｐｏＡ１／ＡｐｏＢ，ＨＤＬＣ，ＬＤＬＣ水平分别为１．２０±０．１９ｇ／Ｌ，１．０７±０．４７ｇ／Ｌ，１．２３±０．３２，１．１４±０．３８ｍｍｏｌ／Ｌ，５．６１±３．１６ｍｍｏｌ／Ｌ。对照组分别为１．３４±０．２２ｇ／Ｌ，０．７４±０．１２ｇ／Ｌ，１．７５±０．２４，１．３７±０．２２ｍｍｏｌ／Ｌ，２．２９±０．７０ｍｍｏｌ／Ｌ。两组间的各项结果差异均有显著意义（Ｐ＜０．０５）。不同类型肾病患者该５项指标的阳性率及异常幅度各不相同。结论联合测定ＡｐｏＡ１、ＡｐｏＢ、ＡｐｏＡ１／ＡｐｏＢ、ＨＤＬＣ、ＬＤＬＣ能提高危险因素的检出率，对早期发现及预防肾脏心血管并发症具有重要意义。
Objective To determine the indicators of lipid metabolism for the early detection of renal disease secondary hyperlipidemia, atherosclerotic cardiovascular complications provide a diagnostic basis. Methods Serum apolipoprotein A1, B, high density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (HDLC) were measured in 55 patients with kidney disease without cardiovascular complications and 52 healthy people by immunoturbidimetry and enzyme assay. Density lipoprotein cholesterol (LDLC). Results The levels of ApoA1, ApoB, ApoA1 / ApoB, HDLC and LDLC in nephropathy group were 1.20 ± 0.19g / L, 1.07 ± 0.47g / L, 1.23 ± 0.32 and 1.14 ± 0.38mmol / L, 5.61 ± 3.16mmol / L. The control group were 1.34 ± 0.22g / L, 0.74 ± 0.12g / L, 1.75 ± 0.24,1.37 ± 0.22mmol / L, 2.29 ± 0.70mmol / L. The differences between the two groups were significant (P <0.05). Different types of patients with kidney disease of the five indicators of the positive rate and abnormal amplitude vary. Conclusions The combined detection of ApoA1, ApoB, ApoA1 / ApoB, HDLC and LDLC can increase the detection rate of risk factors and is of great significance for the early detection and prevention of cardiovascular complications of kidney.